Yahoo Finance Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares
Richard Levy, Director of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), has sold 11,000 shares of the company on April 1, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $257.48 per share, resulting in a total value of $2,832,280.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel therapies that can treat metabolic and cardiovascular diseases. The company's lead candidate, MGL-3196, is being evaluated for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases.
Over the past year, the insider has sold a cumulative total of 11,000 shares and has not made any share purchases. This latest transaction continues the trend of insider sales for the company.
The insider transaction history for Madrigal Pharmaceuticals Inc indicates a pattern of insider activity. In the past year, there have been 6 insider buys and 7 insider sells. This activity provides a glimpse into the sentiment insiders have about the company's stock performance and potential future direction.
On the date of the insider's recent sale, shares of Madrigal Pharmaceuticals Inc were trading at $257.48, giving the company a market capitalization of $5.142 billion.
Investors often monitor insider buying and selling as it can provide insights into a company's internal perspective. While insider selling does not always indicate a lack of confidence in the company, it can prompt shareholders to consider the potential reasons behind the transactions.
For more detailed information on insider transactions and stock performance for Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), interested parties can refer to the full SEC filings and explore the company's financials and market position.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
